Literature DB >> 17823946

ISBT 128 implementation plan for cellular therapy products.

Paul Ashford, Pat Distler, Adrian Gee, Alan Lankester, Stella Larsson, Irene Feller, Kathy Loper, Derwood Pamphilon, Leigh Poston, Fran Rabe, Ineke Slaper-Cortenbach, Zbigniew Szczepiorkowski, Phyllis Warkentin.   

Abstract

The publication of new standards for terminology and labeling marks an important step in ensuring consistency and traceability of cellular therapies at the global level. However, it is only with the widespread implementation of the standard that the benefits can be truly realized. This paper provides guidance on the practical aspects of adopting these new standards for organizations with differing current levels of computerization. It discusses project management, equipment, licensing, and validation topics. Copyright 2007 Internal Cellular Therapy Coding and Labeling Advisory Group.

Entities:  

Mesh:

Year:  2007        PMID: 17823946     DOI: 10.1002/jca.20146

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  3 in total

1.  ISBT 128 coding and labeling for cellular therapy products.

Authors:  Ineke Slaper-Cortenbach
Journal:  Cell Tissue Bank       Date:  2010-09-21       Impact factor: 1.522

2.  ISBT 128: a global information standard.

Authors:  Pat Distler
Journal:  Cell Tissue Bank       Date:  2010-07-21       Impact factor: 1.522

3.  Implementation of an ISBT 128-Compatible Medical Record System to Facilitate Traceability of Stem Cell Products.

Authors:  Can Boğa; Erkan Maytalman; Çiğdem Gereklioğlu; Süheyl Asma; Fatih Kandemir; Pelin Aytan; Aslı Korur; Mahmut Yeral; İlknur Kozanoğlu; Hakan Özdoğu
Journal:  Turk J Haematol       Date:  2017-04-26       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.